lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
319 rows where filing_period = "third_quarter", filing_year = 2019 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2337392 | CONNECT 4 STRATEGIES, LLC c2027d6d-0799-411e-b9ff-477ebffbd1be | Q3 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2019 | third_quarter | PHA | Medicare and Medicaid access | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-09-28T13:11:09.150000-04:00 | |
| 2337395 | CONNECT 4 STRATEGIES, LLC e7de7d5e-af0b-4c91-b6ab-d7432db74826 | Q3 | CONNECT 4 STRATEGIES, LLC | 401103720 | RECORDATI RARE DISEASES | 2019 | third_quarter | PHA | CMS Issues | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-09-28T14:44:13.140000-04:00 | |
| 2337397 | CONNECT 4 STRATEGIES, LLC 8ce5a9b4-fbd4-4d39-918a-b44b566a523f | Q3 | CONNECT 4 STRATEGIES, LLC | 401103720 | AKCEA THERAPEUTICS, INC. | 2019 | third_quarter | PHA | FDA drug approval issues | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2019-09-28T14:55:14.820000-04:00 | |
| 2337398 | CONNECT 4 STRATEGIES, LLC 2866cdd0-fdb5-48d5-ba29-1f13ac6fabf7 | Q3 | CONNECT 4 STRATEGIES, LLC | 401103720 | FERRING PHARMACEUTICALS, INC. | 2019 | third_quarter | PHA | Medicare issues | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-09-28T14:58:15.697000-04:00 | |
| 2337709 | MCDERMOTT WILL & SCHULTE LLP f47834aa-8f07-4b4f-91d0-f2cdb2640f71 | Q3 | MCDERMOTT WILL & SCHULTE LLP | 24338 | MAXOR NATIONAL PHARMACY SERVICES, LLC | 2019 | third_quarter | PHA | Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, S. 1895, S. 2543 and H.R. 3. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2019-10-01T15:02:11.140000-04:00 | |
| 2337916 | AMERICAN COLLEGE OF CLINICAL PHARMACY 9297e66e-eb69-45df-a2c1-d3c66673a028 | Q3 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2019 | third_quarter | PHA | Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2019-10-02T10:28:01.477000-04:00 | |
| 2338085 | JOHNSON MATTHEY INC. f63af658-a856-49af-874f-603dc8b08a07 | Q3 | JOHNSON MATTHEY INC. | 401104441 | JOHNSON MATTHEY INC. | 2019 | third_quarter | PHA | H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. | HOUSE OF REPRESENTATIVES,White House Office | 30000 | 0 | 0 | 2019-10-02T18:35:40.497000-04:00 | |
| 2338809 | ACG ADVOCACY a510e01f-0686-4a64-a34d-b3ba410adba6 | Q3 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2019 | third_quarter | PHA | Drug Pricing Policy Issues. Data privacy and DIR fee reform. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-10-05T15:52:10.117000-04:00 | |
| 2338913 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2a79a300-6778-42df-b9f9-c484af3317b3 | Q3 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2019 | third_quarter | PHA | Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-07T11:12:59.730000-04:00 | |
| 2339018 | RUBICON ADVISORS, LLC 253f7c02-2c02-4748-bbdb-9e93210217cf | Q3 | RUBICON ADVISORS, LLC | 315091 | DYNAVAX TECHNOLOGIES | 2019 | third_quarter | PHA | Prescription Drug User Fee | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2019-10-07T14:14:53.783000-04:00 | |
| 2339060 | RUBICON ADVISORS, LLC 9c0cd06d-4a8d-4dee-a131-0ad15b643148 | Q3 | RUBICON ADVISORS, LLC | 315091 | DR. REDDY'S LABORATORIES, LTD | 2019 | third_quarter | PHA | Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 45000 | 0 | 0 | 2019-10-07T15:08:26.850000-04:00 | |
| 2339062 | RUBICON ADVISORS, LLC e7dabcdb-d0c1-470e-a2e4-5943142c296c | Q3 | RUBICON ADVISORS, LLC | 315091 | CONSCIOUS DISCIPLINE | 2019 | third_quarter | PHA | Medicare | HOUSE OF REPRESENTATIVES,SENATE | 37500 | 0 | 0 | 2019-10-07T15:09:28.900000-04:00 | |
| 2339215 | REPUBLIC CONSULTING, LLC e6542e6e-362a-46df-892a-c6536d33ddaf | Q3 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2019 | third_quarter | PHA | Monitor Data and Science Policy. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-08T10:44:17.160000-04:00 | |
| 2339666 | MS. TAMI WAHL 149c6930-5c71-429b-b9b0-804ceb09ee2e | 3T | MS. TAMI WAHL | 401104405 | PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF US COMPOUNDING PHARMACY | 2019 | third_quarter | PHA | Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2019-10-09T12:23:28.813000-04:00 | ||
| 2339671 | MS. TAMI WAHL 8ac88a1b-97d6-4121-86e6-263dc484963f | 3T | MS. TAMI WAHL | 401104405 | PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF OLYMPIA PHARMACY | 2019 | third_quarter | PHA | Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2019-10-09T12:26:35.897000-04:00 | ||
| 2339674 | MS. TAMI WAHL f36e0a3e-ee4e-4964-9264-28ead668442a | 3T | MS. TAMI WAHL | 401104405 | PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF FAGRON | 2019 | third_quarter | PHA | Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2019-10-09T12:29:36.960000-04:00 | ||
| 2339677 | MS. TAMI WAHL 0522f5ae-233e-406e-86db-503d01b2e549 | 3T | MS. TAMI WAHL | 401104405 | PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF BELMAR SELECT OUTSOURCING | 2019 | third_quarter | PHA | Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2019-10-09T12:31:38.167000-04:00 | ||
| 2340007 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 4df7fbe2-8d83-4d81-a7b4-4ba38aff6664 | Q3 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2019 | third_quarter | PHA | Drug pricing, PCORI re-authorization, 340B | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 37650 | 0 | 0 | 2019-10-10T16:04:42.957000-04:00 | |
| 2340131 | MS. TAMI WAHL a64ae7cb-33c7-4bf5-8f75-27a678561c5c | 3T | MS. TAMI WAHL | 401104405 | OSRX, INC. | 2019 | third_quarter | PHA | Worked to ensure appropriate implementation of federal regulations and standards by providing background on pharmacy compounding and updates on imminent concerns to include the Memorandum of Understanding (Food, Drug and Cosmetic Act 503A(b)(3)(B)(ii)) and standards under the FDCA 503A(b)(1). | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2019-10-10T16:05:43.990000-04:00 | ||
| 2340440 | ISEMAN & ASSOCIATES LLC 254f2e3d-9891-48ca-8ec0-1d2aac4cda7d | Q3 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2019 | third_quarter | PHA | Monitoring biotech legislation; prescription drug prices | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2019-10-11T09:52:58.283000-04:00 | |
| 2340553 | MANATT, PHELPS, AND PHILLIPS 55832956-2029-4555-af60-6765b09d2e5b | Q3 | MANATT, PHELPS, AND PHILLIPS | 23645 | NEKTAR THERAPEUTICS | 2019 | third_quarter | PHA | FDA oversight of certain pain reliever products | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-10-11T11:39:06.153000-04:00 | ||
| 2340557 | CARD & ASSOCIATES, LLC 78a1d3af-a0ac-440a-be4f-2d5a3fe6a9f0 | Q3 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2019 | third_quarter | PHA | Educate Members on pharmacy contracting with pharmacy benefit managers Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing S 1895 Lower Healthcare Costs Act HR 2296 Fair Accountability and Innovative Research Drug Pricing Act HR 2376 Prescription Pricing for the People Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-11T11:41:09.670000-04:00 | |
| 2340677 | SENTRY INSURANCE COMPANY (FORMERLY SENTRY INSURANCE A MUTUAL COMPANY) b39e6d60-b32e-4bc0-a20e-7fa6a75f2c1e | Q3 | SENTRY INSURANCE COMPANY (FORMERLY SENTRY INSURANCE A MUTUAL COMPANY) | 401104022 | SENTRY INSURANCE COMPANY (FORMERLY SENTRY INSURANCE A MUTUAL COMPANY) | 2019 | third_quarter | PHA | Monitoring the folllowing bills H.R 3947, Competition Prescription Act of 2019, all provisions H.R. 2296 METRIC Act, all provisions | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-11T13:55:18.903000-04:00 | |
| 2340746 | MCDERMOTT+ LLC 54c6cef0-6f8b-4a7e-844a-c837c482fe14 | Q3 | MCDERMOTT+ LLC | 401103287 | CAMPAIGN FOR SUSTAINABLE DRUG PRICING | 2019 | third_quarter | PHA | Issues relating to prescription drug pricing S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 340 and H.R. 965 - CREATES Act S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R. 2113 - Prescription Drug STAR Act H.R. 985 - FAST Generics Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2543 - Prescription Drug Pricing Reduction Act of 2019 | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-11T14:31:55.327000-04:00 | |
| 2340907 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) bc7dff3d-05db-41ed-a719-7f9784ac27a1 | Q3 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) | 401105192 | CVS HEALTH | 2019 | third_quarter | PHA | Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. | HOUSE OF REPRESENTATIVES | 45000 | 0 | 0 | 2019-10-12T10:42:55.533000-04:00 | |
| 2340936 | RED+BLUE STRATEGIES 342d36e3-73ba-4521-b954-8b883435e4d5 | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2019 | third_quarter | PHA | H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines. CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. Policies related to the reform of Medicare Part B and D specific to the price of prescription medications. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-13T09:10:22.420000-04:00 | |
| 2340938 | RED+BLUE STRATEGIES 40b518c7-428a-4ef2-a260-3966f9bc943c | Q3 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2019 | third_quarter | PHA | S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. H.R. 3443 - The OTC Monograph Safety Innovation and Reform Act of 2019 - Support for policies that enable OTC monograph reform. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) regarding MAT treatment. Issues related to curbing antibiotic resistance. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-10-13T09:20:24.133000-04:00 | |
| 2340992 | RED+BLUE STRATEGIES 3f04257f-8c42-4ec7-b689-82dd60af0dac | Q3 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2019 | third_quarter | PHA | H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. | Health & Human Services, Dept of (HHS),SENATE | 60000 | 0 | 0 | 2019-10-13T20:34:53.067000-04:00 | |
| 2341049 | INDEPENDENT PHARMACY COOPERATIVE f50ea529-d2a0-4527-8379-e979365e1e95 | Q3 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2019 | third_quarter | PHA | Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale. Proposed Regulation CMS-4180-P Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses. IPC supports. Proposed Regulation - OIG-0936-P Fraud and Abuse Removal of Federal Social Security Act Safe Harbor Protections for Prescription Drug Manufacturer Rebates and Safe Harbor Protections for Prescription Drug Point-of-Sale Price Reductions-IPC supports if a reasonable timeline is given to implement. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-14T09:45:31.787000-04:00 | |
| 2341161 | ICE MILLER LLP eb15131d-40d9-438a-9927-f8ac1841e0c7 | Q3 | ICE MILLER LLP | 67854 | ELI LILLLY AND COMPANY | 2019 | third_quarter | PHA | Issues related to pharmaceutical research and manufacturing | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-10-14T11:00:15.743000-04:00 | ||
| 2341193 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 4d75b65f-b4e2-45fe-8aec-4768260ef9ef | Q3 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | INOVIO PHARMACEUTICALS | 2019 | third_quarter | PHA | Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-14T11:12:30.147000-04:00 | |
| 2341229 | POLSINELLI PC 49c46be6-48a5-47d7-beaf-3e7ade1c352c | Q3 | POLSINELLI PC | 314911 | TEVA PHARMACEUTICALS USA, INC. | 2019 | third_quarter | PHA | S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-10-14T11:24:44.610000-04:00 | |
| 2341929 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES 821d9898-5c59-4cb9-8d07-d12d084307ca | Q3 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 26672 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2019 | third_quarter | PHA | H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 | HOUSE OF REPRESENTATIVES,SENATE | 680000 | 0 | 0 | 2019-10-15T10:44:25.867000-04:00 | |
| 2341979 | WINNING STRATEGIES WASHINGTON 725b98c5-4b3a-4db0-bc21-48f771bf2ace | Q3 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2019 | third_quarter | PHA | Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues | Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-10-15T10:58:44.710000-04:00 | |
| 2342329 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. b70514c2-8879-4d19-a572-aa8956474791 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2019 | third_quarter | PHA | HR 1409, Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2019-10-15T12:21:56.150000-04:00 | |
| 2342341 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 9df4496c-906a-4702-9bf7-a962c48f47b1 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2019 | third_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2019-10-15T12:23:58.997000-04:00 | |
| 2342345 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. c17cdeb2-7fd6-4d1c-aca4-6846ca6a55fe | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2019 | third_quarter | PHA | Issues related to the 340B drug discount program and drug pricing policies | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-15T12:26:00.450000-04:00 | |
| 2342354 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 7b010b90-562f-4336-8358-6830712f09da | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2019 | third_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2019-10-15T12:28:01.967000-04:00 | |
| 2342477 | TAUZIN STRATEGIC NETWORKS 858ef5cf-b058-47e7-818c-5b943a96f6c3 | Q3 | TAUZIN STRATEGIC NETWORKS | 400786367 | CAPTURERX | 2019 | third_quarter | PHA | Issues related to the 340b program | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-15T13:25:38.160000-04:00 | |
| 2342739 | OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 0e492cf6-1860-4980-b941-d3c514db1d97 | Q3 | OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC | 30212 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2019 | third_quarter | PHA | Drug pricing, Direct and Indirect remuneration fees, Medicare | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2019-10-15T14:52:04.970000-04:00 | |
| 2342865 | POLITICAL CAPITAL, LLC 0d8a0f1c-5374-4f2c-b853-f34213c4c2f4 | Q3 | POLITICAL CAPITAL, LLC | 401104260 | MEDISCA INC | 2019 | third_quarter | PHA | Guidance documents, compounding pharmacy, appropriations language. | Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2019-10-15T15:12:33.910000-04:00 | |
| 2342875 | POLITICAL CAPITAL, LLC 86e5bcfd-b943-45da-9ccd-b8dd3cc567e0 | Q3 | POLITICAL CAPITAL, LLC | 401104260 | PINE PHARMACEUTICALS | 2019 | third_quarter | PHA | Guidance documents, compounding pharmacy, appropriations language. | Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-10-15T15:15:37.647000-04:00 | |
| 2342885 | POLITICAL CAPITAL, LLC 8196cd44-39dc-4fa5-9d3f-aec9ac4369ec | Q3 | POLITICAL CAPITAL, LLC | 401104260 | STOKES PHARMACY | 2019 | third_quarter | PHA | Compounding | Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-10-15T15:16:40.117000-04:00 | |
| 2342894 | POLITICAL CAPITAL, LLC 3fd880bb-6d90-40f5-98f4-bbd378c53178 | Q3 | POLITICAL CAPITAL, LLC | 401104260 | KRS GLOBAL BIOTECHNOLOGY INC | 2019 | third_quarter | PHA | Compounding | Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-10-15T15:17:43.540000-04:00 | ||
| 2343072 | BROYDRICK & ASSOCIATES ef085c5d-b8dc-4607-8eff-71036a596650 | Q3 | BROYDRICK & ASSOCIATES | 7268 | EXELA PHARMA SCIENCES | 2019 | third_quarter | PHA | Drug shortages and FDA approval. USTR acceptance. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-10-15T16:05:35.887000-04:00 | |
| 2343110 | BROYDRICK & ASSOCIATES 6dd0828c-c0ff-4c54-a286-2b1704a49b4a | Q3 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2019 | third_quarter | PHA | Funding new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-10-15T16:16:51.023000-04:00 | |
| 2343130 | HANCE SCARBOROUGH 35d698db-d122-4bc8-98ab-459cbbd0e08f | Q3 | HANCE SCARBOROUGH | 17443 | PHRMA | 2019 | third_quarter | PHA | Patent reform regarding pharmaceutical research & products. SB 1416 by Sen. Cornyn. | SENATE | 20000 | 0 | 0 | 2019-10-15T16:23:02.777000-04:00 | |
| 2343189 | HANCE SCARBOROUGH 0c6bfb22-0c84-4b9b-a2c3-b6d830d6ec36 | Q3 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2019 | third_quarter | PHA | Issues related to the regulation of pharmacy compounding. HR 1959 Preserving Patient Access to Compounded Medications Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-15T16:47:29.550000-04:00 | |
| 2343370 | MR. VINCENT A. PANVINI 521533e8-1831-4daa-8bdb-12ce66c0bb09 | Q3 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2019 | third_quarter | PHA | Position on Price Controls; Intellectual Property Rights; Patent Protections, Importation of Illegal Biopharmaceutical Drugs. | HOUSE OF REPRESENTATIVES,SENATE | 6000 | 0 | 0 | 2019-10-15T21:46:41.603000-04:00 | |
| 2343377 | THE MATHIS HARPLE GROUP e463cc60-6119-4c3b-bfb7-a1c3e80e971f | Q3 | THE MATHIS HARPLE GROUP | 322911 | PILMA | 2019 | third_quarter | PHA | HR 3, Price Controls, Intellectual Property Rights | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-10-15T22:34:46.847000-04:00 | |
| 2343380 | THE MATHIS HARPLE GROUP 4e0e9359-3675-4925-a47d-9df4fa67d6d7 | Q3 | THE MATHIS HARPLE GROUP | 322911 | PHRMA | 2019 | third_quarter | PHA | Price Controls, Intellectual Property Rights, Patent Protections, HR3 | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-10-15T23:06:49.783000-04:00 | |
| 2343428 | MARSHALL & POPP, LLC 2c8df2c3-304b-4428-96ad-34481420fbdf | Q3 | MARSHALL & POPP, LLC | 401105121 | AMGEN USA INC. | 2019 | third_quarter | PHA | Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. 340B issues. Patents and protection of intellectual property issues. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office | 60000 | 0 | 0 | 2019-10-16T08:46:17.793000-04:00 | |
| 2343436 | MARSHALL & POPP, LLC 1f91227c-46fd-41cd-975e-3fe5d99820ba | Q3 | MARSHALL & POPP, LLC | 401105121 | GENENTECH, INC. | 2019 | third_quarter | PHA | Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office | 60000 | 0 | 0 | 2019-10-16T08:56:20.820000-04:00 | |
| 2343456 | MARSHALL & POPP, LLC 1d4ddacd-fcf7-49dc-87aa-505688bcc78c | Q3 | MARSHALL & POPP, LLC | 401105121 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2019 | third_quarter | PHA | Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office | 50000 | 0 | 0 | 2019-10-16T09:10:27.567000-04:00 | |
| 2343466 | MARSHALL & POPP, LLC 5c11de4f-4c88-4fe0-ac8e-c39e8d96389c | Q3 | MARSHALL & POPP, LLC | 401105121 | SANOFI U.S. SERVICES, INC. | 2019 | third_quarter | PHA | Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office | 40000 | 0 | 0 | 2019-10-16T09:19:31.713000-04:00 | |
| 2343747 | WAXMAN STRATEGIES 78516471-d19b-4f54-9922-1224a44a76bf | Q3 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2019 | third_quarter | PHA | Issues affecting the 340B drug pricing program; Appropriations for 340B program. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-16T10:37:20.417000-04:00 | |
| 2344284 | VANTAGEKNIGHT LLC 35b2e889-7407-4bf6-bdc2-43b46b2475cd | Q3 | VANTAGEKNIGHT LLC | 401104100 | CVS HEALTH | 2019 | third_quarter | PHA | Healthcare policy and policy issues related to accessible affordable options for quality pharmaceutical products | 50000 | 0 | 0 | 2019-10-16T13:44:21.740000-04:00 | ||
| 2344436 | NVG, LLC f971c253-257f-4f37-97bc-d06a957a20de | Q3 | NVG, LLC | 76833 | MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS) | 2019 | third_quarter | PHA | FDA oversight of certain pain reliever products. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-10-16T14:23:22.400000-04:00 | |
| 2344851 | BROWN & FORTUNATO, P.C. 7d8fe6df-d11f-41b6-a313-335786e4aa98 | Q3 | BROWN & FORTUNATO, P.C. | 401104878 | PROMPTCARE COMPANIES, INC. | 2019 | third_quarter | PHA | Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program. | Centers For Medicare and Medicaid Services (CMS) | 20000 | 0 | 0 | 2019-10-16T15:55:02.777000-04:00 | |
| 2345016 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION a2a5e2ac-5aff-4516-acf6-c79e5ec4f422 | Q3 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2019 | third_quarter | PHA | Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 S.930 - Allowing Greater Access to Safe and Effective Contraception Act S.1847/H.R. 3296 - Affordability is Access Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 | Commerce, Dept of (DOC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 166000 | 0 | 0 | 2019-10-16T16:39:58.537000-04:00 | |
| 2345134 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 18f9b8ad-22df-4c98-9353-1729429a793c | Q3 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2019 | third_quarter | PHA | H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019; | Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office | 320000 | 0 | 0 | 2019-10-16T17:33:37.973000-04:00 | |
| 2345253 | MEHLMAN CONSULTING, INC. b71498e6-8425-4896-8bf5-7e204cfb3f85 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | FOOD ALLERGY RESEARCH & EDUCATION (FARE) | 2019 | third_quarter | PHA | Labeling of allergens. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-16T18:31:13.883000-04:00 | |
| 2345265 | MEHLMAN CONSULTING, INC. babb21df-6f88-4f55-be33-558e47b34c50 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | BLUE SHIELD OF CALIFORNIA | 2019 | third_quarter | PHA | Prescription drug pricing. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-16T18:37:19.060000-04:00 | |
| 2345595 | AMERICAN VETERINARY MEDICAL ASSOCIATION 23545098-0460-4219-bee0-16b20113f047 | Q3 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2019 | third_quarter | PHA | H.R. 1607/S. 1290 Fairness to Pet Owners Act | Agriculture, Dept of (USDA),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2019-10-17T09:27:45.363000-04:00 | |
| 2345981 | GOVERNMENT COUNSEL, LLC 772f34ae-78a3-4b0f-b1ba-f172fb180495 | Q3 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2019 | third_quarter | PHA | Issues related to ARCOS data and suspicious order record requirements and reporting; H.R.3878-Block, Report, And Suspend Suspicious Shipments Act of 2019; importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA). | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-17T10:53:48.080000-04:00 | |
| 2346025 | CAPITOL STRATEGIES GROUP, LLC e8ace7e4-e3c3-42c5-bf7c-3390f1d89084 | Q3 | CAPITOL STRATEGIES GROUP, LLC | 400462294 | PHRMA (ON BEHALF OF WE WORK FOR HEALTH ) | 2019 | third_quarter | PHA | Medicare Part B Medicare Part D Price Indexing Importation | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-17T11:00:00.117000-04:00 | |
| 2346324 | THE ROTUNDA GROUP LLC 8c735f92-3d88-4bd8-823a-510c8dcdb9c4 | Q3 | THE ROTUNDA GROUP LLC | 401104124 | MAGNA PHARMACEUTICALS, INC. | 2019 | third_quarter | PHA | illegal drug control policy | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 7500 | 0 | 0 | 2019-10-17T11:47:50.720000-04:00 | |
| 2346329 | LUNGREN LOPINA LLC 93177d34-7366-4f88-8671-01d649d8b56b | Q3 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2019 | third_quarter | PHA | Fair treatment for US pharmaceutical ingredients | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-10-17T11:47:52.267000-04:00 | |
| 2346718 | BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 8c4a0f49-065c-48f6-a495-6106f5ca5661 | Q3 | BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. | 323876 | BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 2019 | third_quarter | PHA | Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Rx Rebates; Biosimilars H.R. 1781 -- 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R. 938 -- 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 -- 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R. 1503 -- 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R. 1499 -- 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R. 965 -- 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] | HOUSE OF REPRESENTATIVES,SENATE | 5000 | 0 | 0 | 2019-10-17T13:03:06.023000-04:00 | |
| 2346745 | UNIVERSITY OF IOWA f454332b-76f1-4a6a-93ab-ba00a31c481f | Q3 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2019 | third_quarter | PHA | N/A | Commerce, Dept of (DOC),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE | 50000 | 0 | 0 | 2019-10-17T13:12:16.480000-04:00 | |
| 2347094 | BLUE CROSS BLUE SHIELD OF MICHIGAN 68e10de1-681e-43b4-a43d-32ebe0808df4 | Q3 | BLUE CROSS BLUE SHIELD OF MICHIGAN | 46676 | BLUE CROSS BLUE SHIELD OF MICHIGAN | 2019 | third_quarter | PHA | Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; Drug patents H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.275 - 116th Congress (2019-2020) Medicare Prescription Drug Price Negotiation Act of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large] H.R.448 - 116th Congress (2019-2020) Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] | HOUSE OF REPRESENTATIVES,SENATE | 97200 | 0 | 0 | 2019-10-17T14:11:12.277000-04:00 | |
| 2347185 | CAREFIRST BLUECROSS BLUESHIELD f7f346a7-b440-4cb7-9834-d37d2f95a86c | Q3 | CAREFIRST BLUECROSS BLUESHIELD | 401104608 | CAREFIRST BLUECROSS BLUESHIELD | 2019 | third_quarter | PHA | Opioids; CREATES Act; Drug Pricing; Rebates H.R. 1499 - Protecting Consumer Access to Generic Drug Act H.R. 965 - CREATES Act of 2019 | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2019-10-17T14:29:43.243000-04:00 | |
| 2347309 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. ead407ec-a383-460c-8d9c-f3e6a5985ea2 | Q3 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 6382 | BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 2019 | third_quarter | PHA | Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Direct to Consumer Rx Advertising; Biosimilars; Drug Approval; Drug Patents HR 3 (116th Congress), Lower Drug Costs Now Act of 2019, by Rep. Frank Pallone, Jr. (D-NJ). To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes. HR 275 (116th Congress), Medicare Prescription Drug Price Negotiation Act of 2019, by Rep. Peter Welch (D-VT). To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries. HR 448 (116th Congress), Medicare Drug Price Negotiation Act, by Rep. Elijah Cummings (D-MD). To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes. HR 938 (116th Congress), Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (the BLOCKING Act) of 2019, by Rep. Kurt Schrader (D-OR). To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes. HR 965 (116th Congress), CREATES Act of 2019, by Rep. David Cicilline (D-RI). To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. HR 1046 (116th Congress), Medicare Negotiation and Competitive Licensing Act of 2019, by Rep. Lloyd D… | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office | 260000 | 0 | 0 | 2019-10-17T14:42:19.507000-04:00 | |
| 2347362 | HOLLAND & KNIGHT LLP 5f88b167-bd2d-42fc-a740-75e305d1ef43 | Q3 | HOLLAND & KNIGHT LLP | 18466 | TEVA PHARMACEUTICALS USA, INC. | 2019 | third_quarter | PHA | Drug pricing; Intellectual property; S.1895, Lower Health Care Costs Act; S.1416, Affordable Prescriptions for Patients Act of 2019. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-10-17T14:51:43.733000-04:00 | |
| 2347796 | ASSOCIATION OF AMERICAN MEDICAL COLLEGES 9e6dc4a3-22f3-4ae2-9998-cf36a536818c | Q3 | ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 4493 | ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 2019 | third_quarter | PHA | H.R. 965/S.340, The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 H.R. 985, The Fair Access for Safe and Timely (FAST) Generics Act of 2019 H.R. 1520, The Purple Book Continuity Act of 2019 H.R. 1503, The Orange Book Transparency Act of 2019 S. 659: Biologic Patent Transparency Act S. 617: Second Look at Drug Patents Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 US-Mexico-Canada Agreement Issue: Support policies to reduce prescription drug prices | Agency for Healthcare Research & Quality (AHRQ),Bureau of Citizenship & Immigration Services (BCIS),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Education, Dept of,Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Natl Science Foundation (NSF),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Science & Technology Policy (OSTP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office | 1127000 | 0 | 0 | 2019-10-17T15:39:24.307000-04:00 | |
| 2347916 | PUBLIC CITIZEN 13a3129a-804e-4ff7-8211-3a960271afd8 | Q3 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2019 | third_quarter | PHA | HR 1046, S 377-Medicare Negotiation and Competitive Licensing Act, S 1987-End Price Gouging for Medications act, HR 3199-TERM Act, S 1895-Lower Health Care Costs Act, S 1209-(REMEDY act), S 1416-Affordable Prescriptions for Patients Act, HR 2374, S 1224-Stop STALLING Act, HR 3379-PRICED Act, HR 2296, S 1391-(FAIR Drug Pricing Act), drug pricing, HR 2296-METRIC Act, S 2004-Emergency Access to Insulin Act, S 2387-We protect American Investments in Drugs Act (We PAID Act), S 2199-Insulin Price Reduction Act, S 977-Transparent Drug Prices Act, S 378-Stop Price Gouging Act, S 340-CREATES Act, HR 3- Patient Advocacy Transparency Act, | HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR) | 70000 | 0 | 0 | 2019-10-17T15:52:00.927000-04:00 | |
| 2348003 | NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS b8f82ead-334f-4c00-940b-3dfeefe97de4 | Q3 | NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS | 26808 | NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS | 2019 | third_quarter | PHA | HR 3: A bill to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes. S 2543: A bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes. HR 3276: A bill to amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes. HR 2113: A bill to a mend titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes. S. 1895: A bill to lower health care costs by preventing surprise medical bills, reducing prescription drug prices, improving transparency in health care, investing in public health and improving health information exchange. H.R. 1384: This bill establishes a national health insurance program that is administered by the Department of Health and Human Services (HHS). S. 1129: This bill establishes a national health insurance program that is administered by the Department of Health and Human Services (HHS). S. 981: A bill to establish a public health plan. HR 938: A bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes HR 1520: A bill to amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and … | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of,White House Office | 330000 | 0 | 0 | 2019-10-17T16:04:26.673000-04:00 | |
| 2348128 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 2acac252-c0df-495a-93fd-73f03163e555 | Q3 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2019 | third_quarter | PHA | Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 330432 | 0 | 0 | 2019-10-17T16:27:10.550000-04:00 | |
| 2348162 | KOUNTOUPES DENHAM CARR & REID, LLC 2c2c452b-17f3-4689-94ec-1b5527adde6d | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) | 2019 | third_quarter | PHA | Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-17T16:32:20.010000-04:00 | |
| 2348827 | PARAGON BIOSCIENCES, LLC 9b59a851-4fbf-42a5-a017-7782a7894ea4 | Q3 | PARAGON BIOSCIENCES, LLC | 401105338 | PARAGON BIOSCIENCES, LLC | 2019 | third_quarter | PHA | Issues related to public and private investment in biosciences and R&D S. 1249, American Innovation Act H.R. 2401, American Cures Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-10-17T20:12:14.943000-04:00 | |
| 2348951 | FORGE FEDERAL AFFAIRS LLC bdad1fd6-14dc-472f-b536-abc9acf89ba7 | Q3 | FORGE FEDERAL AFFAIRS LLC | 400865535 | LILLY USA LLC | 2019 | third_quarter | PHA | Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019. | HOUSE OF REPRESENTATIVES | 20000 | 0 | 0 | 2019-10-17T22:53:12.433000-04:00 | |
| 2349150 | BLUE CROSS AND BLUE SHIELD ASSOCIATION 27d004e4-246a-4dcc-b6d8-9cbdcec32bc7 | Q3 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2019 | third_quarter | PHA | Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; Drug patents H.R.1781 - 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 - 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.275 - 116th Congress (2019-2020) Medicare Prescription Drug Price Negotiation Act of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large] H.R.448 - 116th Congress (2019-2020) Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office | 1530000 | 0 | 0 | 2019-10-18T09:05:39.883000-04:00 | |
| 2349242 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 1a182948-fc19-4896-ad7f-dfe2c180f746 | Q3 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2019 | third_quarter | PHA | HR 4392- To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. H.R. 3. Lower Prescription Drug Costs Now Act - legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 6852 | 0 | 0 | 2019-10-18T09:25:12.823000-04:00 | |
| 2349438 | TRAVERE THERAPEUTICS fb7bb0da-df4b-45e6-974f-4fbadce52a04 | Q3 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2019 | third_quarter | PHA | H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 180000 | 0 | 0 | 2019-10-18T09:48:17.140000-04:00 | |
| 2349673 | LINCOLN PARK GROUP L.L.C. e3bb5672-cd5c-4de5-a682-971cadefd70c | Q3 | LINCOLN PARK GROUP L.L.C. | 401104374 | CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2019 | third_quarter | PHA | Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-10-18T10:18:39.027000-04:00 | |
| 2349704 | VAN SCOYOC ASSOCIATES 023b9ca5-5f0b-4928-977c-60cc2448dde1 | Q3 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2019 | third_quarter | PHA | Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-10-18T10:20:46.467000-04:00 | |
| 2349807 | FARRAGUT PARTNERS LLP 51f0f6d8-de2d-4f05-8315-13ae7e871036 | Q3 | FARRAGUT PARTNERS LLP | 401103938 | COMMUNITY ONCOLOGY ALLIANCE | 2019 | third_quarter | PHA | Issues related to pharmacy benefit managers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-10-18T10:29:10.427000-04:00 | |
| 2349836 | MASSACHUSETTS MEDICAL SOCIETY 5265b21a-216c-4cab-8ae6-959dfce98db5 | Q3 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2019 | third_quarter | PHA | Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-10-18T10:31:20.037000-04:00 | |
| 2349974 | MCDERMOTT+ LLC 05a9e20f-c44f-4232-b774-d176f5ccc062 | Q3 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2019 | third_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-18T10:42:08.687000-04:00 | |
| 2350025 | TARPLIN, DOWNS & YOUNG, LLC 52812dae-4f60-4408-aa2f-7ec4ecc84740 | Q3 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2019 | third_quarter | PHA | Importation of prescription drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844) Opioid Abuse - General issues related to opioid drug abuse (Implementation of Public Law 115-271) Implementation of Public Law 113-54 (DSCSA) Issues Related to ARCOS data and suspicious order record requirements & reporting | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-10-18T10:46:30.863000-04:00 | |
| 2350133 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 021e5079-612e-48fd-bb08-0f1ea6df6f4b | Q3 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2019 | third_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 350000 | 0 | 0 | 2019-10-18T10:53:08.447000-04:00 | |
| 2350456 | ELI LILLY AND COMPANY 85b80e6e-606a-4bd8-8b08-33d6bbd9c57d | Q3 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2019 | third_quarter | PHA | Hospital discounts; 340B program | Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1370000 | 0 | 0 | 2019-10-18T11:17:18.093000-04:00 | |
| 2350815 | HIGHMARK, INC. 7458a6e8-bda7-4964-8dc5-d23f289163a7 | Q3 | HIGHMARK, INC. | 18238 | HIGHMARK INC | 2019 | third_quarter | PHA | (Epidemic, Deterrence); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Biosimilars; Drug approval; Drug patents H.R.1781 - Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 -BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] H.R.3 - Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large] H.R.448 - Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] H.R.1046 - Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] | HOUSE OF REPRESENTATIVES,SENATE | 300000 | 0 | 0 | 2019-10-18T11:48:06.357000-04:00 | |
| 2350959 | UC HEALTH 96d83d09-ec97-4c91-abea-02f632ea7e24 | Q3 | UC HEALTH | 401103195 | UC HEALTH | 2019 | third_quarter | PHA | 340B, drug prices | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-10-18T12:02:04.227000-04:00 | ||
| 2350999 | FTI GOVERNMENT AFFAIRS 6fcfd307-9a0d-4c9d-9ae4-d1d4f316f293 | Q3 | FTI GOVERNMENT AFFAIRS | 401054971 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2019 | third_quarter | PHA | Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-18T12:04:15.470000-04:00 | |
| 2351100 | KOUNTOUPES DENHAM CARR & REID, LLC 13ec6bbf-09e2-4b15-ad14-6b1515d1bfe2 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2019 | third_quarter | PHA | General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H.R.269 and H. R. 3443, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-18T12:09:34.350000-04:00 | |
| 2351309 | GREATER NEW YORK HOSPITAL ASSOCIATION eae21c0e-0b7b-4d5c-ae2c-bb8bdd3684b8 | Q3 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2019 | third_quarter | PHA | Discuss issues related to group purchasing organizations (GPOs) with Congressional staff and members. Discuss several pieces of legislation with Congressional staff including: the CREATES Act (H.R. 965/S. 340) (support), the Fast Access for Safe & Timely Generics Act (H.R. 985) (support), the Protecting Consumer Access to Generic Drugs Act (H.R. 1499) (support), the Fair and Immediate Release of Generic Drugs Act (H.R. 1506) (support), the Orange Book Transparency Act (H.R. 1503) (support), the Purple Book Continuity Act (H.R. 1520) (support), and the Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics Act (H.R. 938) (support). Discuss the METRIC Act (H.R. 2296) with Congressional staff. Discuss potential legislation to address drug shortages with Congressional staff. Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff. Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),President of the U.S.,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office | 650000 | 0 | 0 | 2019-10-18T12:34:32.370000-04:00 | |
| 2351441 | KOUNTOUPES DENHAM CARR & REID, LLC 8108d9ae-8f16-41b0-bb84-d9e8dc75ff2e | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2019 | third_quarter | PHA | General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. Issues related to S.1895, the Lower Health Care Costs Act. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-10-18T12:57:16.640000-04:00 | |
| 2351870 | BURRELL INTERNATIONAL GROUP LLC badd5570-c705-4e56-86b7-edfeae97ba4d | Q3 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | ACER THERAPEUTICS | 2019 | third_quarter | PHA | No specific legislative vehicles. Issues are, generally, orphan drug legislation, rare disease legislation, drug pricing policy | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-10-18T13:50:35.470000-04:00 | |
| 2352091 | SAS INSTITUTE 4b98b138-dee7-4880-b7f3-015237c0a30b | Q3 | SAS INSTITUTE | 53243 | SAS INSTITUTE | 2019 | third_quarter | PHA | Issues relating to the role of data and analytics to provide better insight for Centers for Medicare and Medicaid Services work on reducing drug prices | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Interior, Dept of (DOI),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),Overseas Private Investment Corp (OPIC),SENATE,White House Office | 530000 | 0 | 0 | 2019-10-18T14:20:38.217000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);